合并非酒精性脂肪性肝病对恩替卡韦治疗慢性乙型肝炎患者抗病毒疗效的影响

doi:10.3969/j.issn.1672-5069.2021.03.010

摘要/Abstract

摘要： 目的探讨合并非酒精性脂肪性肝病(NAFLD)对慢性乙型肝炎(CHB)患者抗病毒治疗疗效的影响。方法 2015年1月～2019年1月我院诊治的HBeAg阳性的初治的CHB患者289例,其中合并NAFLD患者102例,未合并NAFLD患者187例。给予所有患者恩替卡韦治疗,观察96 w。结果合并NAFLD患者体质指数为(26.1±2.7)kg/m²,显著高于CHB组【(22.5±2.4)kg/m²,P<0.05】,血尿酸水平为(405.1±125.8)μmol/L,显著高于CHB组【(324.6±96.8)μmol/L,P<0.05】,血清总胆固醇为(5.3±0.9 mmol/l,显著高于CHB组【(4.2±0.9)mmol/l,P<0.05】,血清甘油三酯水平为(3.5±0.7)mmol/l,显著高于CHB组【(1.9±0.5) mmol/l,P<0.05】,血清低密度脂蛋白水平为(3.4±1.0 mmol/l,显著高于CHB组【(2.3±0.8)mmol/l,P<0.05】,空腹血糖水平为(5.9±1.5)mmol/l,显著高于CHB组【(4.6±0.6) mmol/l,P<0.05】,而两组血清ALT水平(250.8±110.5 U/L对287.2±125.8 U/L)、AST水平(149.1±62.8 U/L对(168.7±70.8) U/L)、高密度脂蛋白水平(1.2±0.5 mmol/l对1.4±0.4mmol/l)和血清HBV DNA水平(6.8±1.2 lg copies/ml对6.9±1.1lg copies/ml)无显著性差异(P>0.05);在治疗48 w和96 w末,合并NAFLD组血清ALT复常率分别为69.6%和81.4%,显著低于CHB组(分别为80.2%和90.9%,P<0.05),而两组血清HBV DNA阴转率(分别为79.4%和87.3%对84.0%和90.9%)和血清HBeAg转阴率(分别为7.8%和7.8%对5.3%和5.9%)比较,无显著性差异(P>0.05)。结论合并NAFLD可影响接受抗病毒治疗的CHB患者血生化学应答,其对组织学的影响及其对长期疗效的影响还有待于观察。

关键词: 慢性乙型肝炎, 非酒精性脂肪性肝病, 恩替卡韦, 治疗

Abstract: Objective The aim of this study was to investigate the impact of antiviral therapy efficacy of entecavir in patients with chronic hepatitis B (CHB)and concomitant nonalcoholic fatty liver diseases (NAFLD).Methods 289 naïve serum HBeAg positive patients with CHB were enrolled in this study between January 2015 and January 2019, including 102 patients out of them with concomitant US-confirmed NAFLD. All patients received entecavir therapy and followed-up for 96 weeks. The biochemical, serologic and virological response were observed.Results The body mass index in patients with CHB and NAFLD was (26.1±2.7)kg/m², significantly higher than [(22.5±2.4)kg/m², P<0.05] in patients with CHB, serum uric acid l level was (405.1±125.8)μmol/L, significantly higher than [(324.6±96.8)μmol/L, P<0.05] in patients with CHB, serum total cholesterol level was (5.3±0.9 mmol/l, significantly higher than [(4.2±0.9)mmol/l, P<0.05] in patients with CHB, serum triglyceride level was (3.5±0.7)mmol/l, significantly higher than [(1.9±0.5) mmol/l, P<0.05] in patients with CHB, serum low density lipoprotein level was (3.4±1.0 mmol/l, significantly higher than [(2.3±0.8)mmol/l, P<0.05] in patients with CHB, and fasting blood glucose level was (5.9±1.5)mmol/l, significantly higher than [(4.6±0.6) mmol/l, P<0.05] in patients with CHB, while there were no significant differences respect to serum alanine aminotransferase levels (ALT, 250.8±110.5 U/L vs. 287.2±125.8 U/L), serum aspartate aminotransferase level (149.1±62.8 U/L vs. (168.7±70.8) U/L), serum high density lipoprotein level (1.2±0.5 mmol/l vs. 1.4±0.4mmol/l) and serum HBV DNA load (6.8±1.2 lg copies/ml vs. 6.9±1.1lg copies/ml) between the two groups (P>0.05); at the end of 48 week and 96 week treatment, serum ALT normalization rate in CHB patients with concomitant NAFLD were 69.6% and 81.4%, significantly lower than in patients with CHB(80.2% and 90.9%, respectively, P<0.05), while there were no significant differences respect to serum HBV DNA loss (79.4% and 87.3% vs. 84.0% and 90.9%, respectively), and serum HBeAg negative rates (7.8% and 7.8% vs. 5.3% and 5.9%) between the two groups (P>0.05).Conclusion The patients with CHB and concomitant NAFLD could poorly respond to entecavir antiviral therapy biochemically, and the impact on histological and long-term responses needs further investigation.

Key words: Chronic hepatitis B, Nonalcoholic fatty liver disease, Entecavir, Response

陈熙, 王玮, 高健伟, 许乐. 合并非酒精性脂肪性肝病对恩替卡韦治疗慢性乙型肝炎患者抗病毒疗效的影响[J]. 实用肝脏病杂志, 2021, 24(3): 343-346.

Chen Xi, Wang Wei, Gao Jianwei, et al. Impact of antiviral therapy efficacy of entecavir in patients with chronic hepatitis B and concomitant nonalcoholic fatty liver diseases[J]. Journal of Practical Hepatology, 2021, 24(3): 343-346.

参考文献

[1] Di N, Zhou X, Chen Y, et al. Could semiquantitative analysis of real-time ultrasound elastography distinguish more liver parenchyma alterations of nonalcoholic fatty liver disease in patients with polycystic ovary syndrome?. Arch Endocrinol Metab, 2019, 63(2):128-136.
[2]Yang HH, Zhou H, Zhu WZ, et al. Green tea consumption may be associated with cardiovascular disease risk and nonalcoholic fatty liver disease in type 2 diabetics: a cross-sectional study in Southeast China. J Med Food, 2020, 23(10):1120-1127.
[3] Xiao H, Shi M, Xie Y, et al. Comparison of diagnostic accuracy of magnetic resonance elastography and Fibroscan for detecting liver fibrosis in chronic hepatitis B patients:a systematic review and meta-analysis. PLOS One, 2017,12(11):e 0181660.
[4] Ye J, Hu X, Wu T, et al. Insulin resistance exhibits varied metabolic abnormalities in nonalcoholic fatty liver disease, chronic hepatitis B and the combination of the two: a cross-sectional study. Diabetol Metab Syndr,2019,15(11):45.
[5] Zhou WJ, Yang J, Zhang G, et al. Association between red cell distribution width-to-platelet ratio and hepatic fibrosis in nonalcoholic fatty liver disease: A cross-sectional study. Medicine (Baltimore), 2019, 98(30):e16565.
[6] Zhang GL, Xu SC, Zeng J, et al. Optimizing the use of the gamma-glutamyl transpeptidase-to-platelet ratio and transient elastography to identify liver cirrhosis in patients with chronic hepatitis B concurrent with nonalcoholic fatty liver disease. Dis Markers, 2019, 2019:2585409.
[7] Xu N, Xie Q, Li J, et al. Improvement in liver stiffness measurement for diagnosis of liver fibrosis in patients with concurrent chronic hepatitis B and nonalcoholic fatty liver disease. J Int Med Res, 2020, 48(2):300.
[8] Akdo an Ö, Atak Yücel A, Gök Sargin Z, et al. Evaluation of plasma urokinase-type plasminogen activator receptor (UPAR) in patients with chronic hepatitis B, C and non-alcoholic fatty liver disease (NAFLD) as serological fibrosis marker. J Clin Exp Hepatol, 2019, 9(1):29-33.
[9] 中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎防治指南(2019年版).中华传染病杂志,2019,37(12):711-736.
[10] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.非酒精性脂肪性肝病防治指南 (2018年版).实用肝脏病杂志,2018,21(2):177-186.
[11] 徐亮, 钟燕, 苏淑婷, 等.反应性氧化物、脂联素在慢性乙型肝炎病毒感染合并非酒精性脂肪性肝病中的研究.中华肝脏病杂志, 2020, 28(3):247-253.
[12] 高慧, 匡哲, 钟春秀, 等. 接受抗病毒治疗的慢性乙型肝炎患者非酒精性脂肪性肝病的患病率及其危险因素分析. 中华肝脏病杂志, 2019, 27(5):347-351.
[13] Kim SU, Jeon MY, Lim TS. Diagnostic performance of serum asialo-α1-acid glycoprotein for advanced liver fibrosis or cirrhosis in patients with chronic hepatitis B or nonalcoholic fatty liver disease. Korean J Gastroenterol, 2019, 74(6):341-348.
[14] Munteanu M, Pais R, Peta V, et al. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. Aliment Pharmacol Ther, 2018, 48(10):1117-1127.
[15] Ma TL, Hu TH, Hung CH, et al. Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment. PLoS One, 2019,14(10):e0222221.
[16] Zhuang Z, Qu H, Yang W, et al. Comparing hepatic steatosis distribution patterns between non-alcoholic fatty liver disease and fatty liver disease with chronic hepatitis B by second-harmonic generation/two-photon excited fluorescence method. Ann Hepatol, 2020, 19(3):313-319.
[17] Karamolahi S, Yazdi RS, Zangeneh M, et al. Impact of hepatitis B virus and hepatitis C virus infection on sperm parameters of infertile men.Int J Reprod Biomed (Yazd), 2019,17(8):551-556.
[18] Mirhafez SR, Farimani AR, Dehhabe M, et al. Effect of phytosomal curcumin on circulating levels of adiponectin and leptin in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled clinical trial. J Gastrointest Liver Dis, 2019, 28:183-189.
[19] Hwang S, Song GW, Chung YK, et al. Determination of hepatitis B immunoglobulin infusion interval using pharmacokinetic half-life simulation for posttransplant hepatitis B prophylaxis. J Korean Med Sci, 2019,34(38):e251.
[20] Javanmardi MA, Mohammad Shahi M, Seyedian SS, et al. Effects of phytosterol supplementation on serum levels of lipid profiles, liver enzymes, inflammatory markers, adiponectin, and leptin in patients affected by nonalcoholic fatty liver disease: a double-blind, placebo-controlled, randomized clinical trial. J Am Coll Nutr, 2018, 1-8.
[21] Ye J, Hu X, Wu T, et al. Insulin resistance exhibits varied metabolic abnormalities in nonalcoholic fatty liver disease, chronic hepatitis B and the combination of the two: a cross-sectional study. Diabetol Metab Syndr, 2019, 11:45.
[22] Duseja A, Singh SP, Saraswat VA, et al. Non-alcoholic fatty liver disease and metabolic syndrome-position paper of the IndianNational Association for the study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J Clin Exp Hepatol, 2015, 5(1):51-68.
[23] Yamaura Y, Tatsumi N, Takagi S, et al. Serum microRNA profiles in patients with chronic hepatitis B, chronic hepatitis C, primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, or drug-induced liver injury. Clin Biochem, 2017, 50(18):1034-1039.